Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant 500 mg versus anastrozole 1 mg in first-line hormone receptor-positive advanced breast cancer
2011-006326-24Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- Jun 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Fulvestrant arm with Anastrozole arm (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
fulvestrantanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-006326-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006326-24.